Fresenius Medical Care AG & Co. KGaA
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
17.2% vs price
Base Case (Median)
58.1% vs price
Bull Case (75th pct.)
153.4% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $12.22 | -48.0% | High (40%) |
| PE Comparable | $37.16 | 58.1% | Medium (25%) |
| Growth Trajectory DCF | $79.24 | 237.2% | Medium (20%) |
| Graham Number | $30.36 | 29.2% | Medium (40%) |
| EV/EBITDA | $58.33 | 148.2% | Medium (20%) |
| EV/FCF | $60.79 | 158.7% | Medium (20%) |
| Earnings Power Value | $24.72 | 5.2% | Medium (50%) |
Based on 7 out of 8 methods, FMS appears undervalued at the current price of $23.50. The base case fair value of $37.16 implies 58.1% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.